Loading rounds…
Loading rounds…
Explore funding rounds, the companies behind them and the investors taking part.
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| A AbcuroCompany profile Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases | $66M | Series DSeries C+ | Biotech | United States | Investors |
Ranked by rounds participated in · All time
AusperBio, Abcuro, Infinimmune
Epicrispr Biotechnologies, Draig Therapeutics, Triveni Bio
LifeMine Therapeutics, Ollin Biosciences, SonoThera
Leal Therapeutics, Khartis Therapeutics, Vedana Therapeutics
Leal Therapeutics, Amplifica Holdings Group, InduPro
Explore published rounds while the next edition is being prepared.
| LT Develops neuro-metabolic therapeutics for schizophrenia and ALS | $30M | Series A | Biotech | United States | Investors |
| KT Khartis TherapeuticsCompany profile Develops oral small molecule therapies for immunological and chronic diseases Develops oral small molecule therapies for immunological and chronic diseases | $50M | Series B | Biotech | United States | Investors |
| BT Beyang TherapeuticsCompany profile AI-driven drug discovery company using its ExCEED molecular design platform AI-driven drug discovery company using its ExCEED molecular design platform | $30M | Series A | Biotech | China | Investors |
| AH Amplifica Holdings GroupCompany profile Clinical-stage biopharma developing injectable therapies for hair loss Clinical-stage biopharma developing injectable therapies for hair loss | $26M | Series B | Biotech | United States | Investors |
| I InduProCompany profile Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease | $77M | Series B | Biotech | United States | Investors |
| R RemepyCompany profile Develops Hybrid Drugs combining prescription medicines with AI-driven therapeutic apps Develops Hybrid Drugs combining prescription medicines with AI-driven therapeutic apps | $36M | Series A | Biotech | Israel | Investors |
| A Develops nanoantibody therapies to treat sea lice in salmon farming | Undisclosed | Undisclosed | Biotech | Germany | Investors |
| VT Vaderis TherapeuticsCompany profile Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia | $152M | Series B | Biotech | Switzerland | Investors |
| I InfinimmuneCompany profile Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease | $75M | Series A | Biotech | United States | Investors |